HC Wainwright Reiterates Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)
HC Wainwright reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a report issued on Monday,Benzinga reports. They currently have a $69.00 price objective on the stock. Other analysts also recently issued reports about the stock. Bank of America increased their price target on shares of Rhythm Pharmaceuticals from $48.00 […]
More Stories
Head-To-Head Survey: Preferred Bank (NASDAQ:PFBC) vs. Independent Bank Group (NASDAQ:IBTX)
Independent Bank Group (NASDAQ:IBTX – Get Free Report) and Preferred Bank (NASDAQ:PFBC – Get Free Report) are both finance companies,...
NantHealth (NASDAQ:NH) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of NantHealth (NASDAQ:NH – Free Report) in a research note released on Tuesday morning. The...
T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO – Free Report) in a report issued on Monday morning. The...
Barnwell Industries (NYSE:BRN) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Barnwell Industries (NYSE:BRN – Free Report) in a report released on Tuesday morning. The...
Truist Financial (NYSE:TFC) Price Target Raised to $51.00
Truist Financial (NYSE:TFC – Free Report) had its price target lifted by Citigroup from $47.00 to $51.00 in a report...
Rosenblatt Securities Reiterates Neutral Rating for Brightcove (NASDAQ:BCOV)
Rosenblatt Securities reaffirmed their neutral rating on shares of Brightcove (NASDAQ:BCOV – Free Report) in a research note published on...